Charles Schwab Investment Management Inc. raised its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 3.2% in the ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

Guggenheim lowered the firm’s price target on AnaptysBio (ANAB) to $36 from $90 and keeps a Buy rating on the shares following the announcement ...

Wells Fargo analyst Derek Archila lowered the firm’s price target on AnaptysBio (ANAB) to $40 from $56 and keeps an Overweight rating on the ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral. Analyst Price Forecast Suggests 257.63% Upside As of December ...

H.C. Wainwright has recently reduced AnaptysBio Inc (ANAB) stock to Neutral rating, as announced on Today, according to Finviz. Earlier, on December 2, 2024, BTIG Research had reduced the stock from a ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...